Detailed Report on Vascular Endothelial Growth Factor B - Pipeline Review, H1 2017
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.
The latest report Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Complete report available @ Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1). The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 4 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion, Retinopathy and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics and enlists all their major and minor projects
- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics and enlists all their major and minor projects
- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Alteogen Inc CSL Ltd Eli Lilly and Company Formycon AG Regeneron Pharmaceuticals Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 04:09
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home